ArticleRSC advances2026
Engineering matrix-embedded dual-drug eluting biodegradable surgical sutures for prophylaxis against surgical site infections.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in aseptic technique and conventional antimicrobial prophylaxis, surgical site infections (SSIs) remain a leading cause of postoperative morbidity, mortality, and healthcare costs globally. Traditional sutures merely approximate tissue and can harbour microorganisms that drive the emergence of multidrug-resistant pathogens. Thus, SSIs contribute significantly to the spread of antimicrobial resistance (AMR). To address this dual challenge, this study focuses on developing and characterize biodegradable, multi-drug-eluting sutures capable of localised delivery of two therapeutic agents to prevent infection and promote wound healing. Two clinically relevant therapeutic agents, levofloxacin (broad-spectrum antibiotic) and ibuprofen (an anti-inflammatory), were incorporated into biodegradable polycaprolactone (PCL) polymer. Placebo (F1), levofloxacin-only (F2), and dual-drug (F3) biodegradable sutures conforming to the USP 2-0 size specification were successfully fabricated using solvent-free hot-melt extrusion technology. Solid-state analyses (DSC and PXRD), as well as FTIR and Raman spectroscopy, confirmed that the drugs were amorphous and molecularly dispersed in the suture.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.